Park Avenue Securities LLC Grows Stake in Bristol-Myers Squibb (NYSE:BMY)

Park Avenue Securities LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 17.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,779 shares of the biopharmaceutical company's stock after purchasing an additional 9,973 shares during the quarter. Park Avenue Securities LLC's holdings in Bristol-Myers Squibb were worth $4,073,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. LaFleur & Godfrey LLC boosted its stake in Bristol-Myers Squibb by 3.5% during the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after buying an additional 1,487 shares during the last quarter. Brighton Jones LLC boosted its stake in Bristol-Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. Strategic Financial Concepts LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $4,377,000. Vest Financial LLC boosted its stake in Bristol-Myers Squibb by 15.0% during the fourth quarter. Vest Financial LLC now owns 9,746 shares of the biopharmaceutical company's stock worth $551,000 after buying an additional 1,271 shares during the last quarter. Finally, Quotient Wealth Partners LLC boosted its stake in Bristol-Myers Squibb by 98.4% during the fourth quarter. Quotient Wealth Partners LLC now owns 8,649 shares of the biopharmaceutical company's stock worth $489,000 after buying an additional 4,290 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The shares were acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.09% of the stock is owned by company insiders.

Analyst Ratings Changes

BMY has been the topic of a number of recent research reports. Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Wall Street Zen lowered Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Piper Sandler started coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Trading Down 1.9%

Shares of BMY stock traded down $0.99 on Friday, hitting $49.71. The stock had a trading volume of 9,394,854 shares, compared to its average volume of 13,000,634. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The firm has a market capitalization of $101.15 billion, a P/E ratio of -11.25, a P/E/G ratio of 2.07 and a beta of 0.38. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company's 50 day moving average price is $48.78 and its 200-day moving average price is $54.83.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the business earned ($4.40) EPS. The company's quarterly revenue was down 5.6% compared to the same quarter last year. Analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.